ClinicalTrials.gg
RecruitingNCT05881239Updated Mar 6, 2026

Digital Accessible Remote Olfactory Mediated Health Assessments for Preclinical AD

An observational study in Subjective Cognitive Concerns, Mild Cognitive Impairment and Mild Behavioral Impairment, sponsored by Massachusetts General Hospital. Recruiting at 1 site in United States. Open to participants aged 18 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-06.

Sponsored by Massachusetts General Hospital · Observational

How we know

From the registry’s dates

  • Started May 2023; still recruiting 3 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
250
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies in Cognitive Dysfunction by Massachusetts General Hospital — 14 open to participants now, 16 under way, none of them phase 3. Cognitive Dysfunction · Massachusetts General Hospital.

Started
2023
with 4 others
Observational
6 of 33
4 open now
Primary completion
2026-12
later than 2 of 15 live
Registered
18th of 33
by date

Among the 33 studies in Cognitive Dysfunction by Massachusetts General Hospital, this one is one of 5 that started in 2023, is one of 6 observational ones, reaches primary completion later than 2 of the 15 other live ones, and was the 18th registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

14 of the 33 studies in Cognitive Dysfunction by Massachusetts General Hospital are open now, in 1 country. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 14 open studies →

Where they have run

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Cognitive Dysfunction by Massachusetts General Hospital, or all of them as a file.
02

Study summary

The goal of this study is to objectively test one's sense of smell, called olfaction, in participants with Subjective Cognitive Concerns (SCC), Mild Cognitive Impairment, Mild Behavioral Impairment (MBI), and age-matched controls. The main question it aims to answer is whether the AROMHA Brain Health Test could serve as a predictive biomarker of neurodegenerative disorders. This understanding will aid in the development of a noninvasive, cost-effective diagnostic tool that reliably and specifically distinguishes disease and normal aging populations.

Participants will take the approximately 45-minute AROMHA Brain Health Smell Test where they will peel and sniff labels on the physical smell cards and answer questions on the web-based app relating to what they smelled. Participants will undergo tests for odor intensity, odor identification, odor discrimination, and episodic olfactory memory, but will not be provided the results of these tests.

03

Conditions studied

  • Subjective Cognitive Concerns
  • Mild Cognitive Impairment
  • Mild Behavioral Impairment
  • Healthy Aging

Keywords

  • Alzheimer's disease
  • Olfactory
  • Neurodegeneration
  • Mild Cognitive Impairment
  • Mild Behavioral Impairment
  • Subjective Cognitive Concerns
  • Olfactory dysfunction
  • Biomarker
  • Cognitive Assessment
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

  1. Subjective Cognitive Concerns (SCC),
  2. Mild Cognitive Impairment,
  3. Mild Behavioral Impairment,
  4. Healthy Age-matched Controls.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A clinical or research consensus diagnosis of the patient's condition or control status.
  • Individuals that are at least 18 years of age at the time of enrollment.
  • Individuals that are no older than 100 years of age at the time of enrollment.

Exclusion criteria

Exclusion Criteria:

  • Primary pulmonary disease such as severe emphysema or asthma not under good medical control.
  • Current sinusitis, common cold, upper respiratory infection, or nasal polyps.
  • Current or recent (past 6 months) alcohol or substance dependence. A prior history of alcohol or substance abuse will not be grounds for exclusion.
  • Pregnancy.
  • Severe cognitive dysfunction that would preclude completion of the olfactory testing.
  • An adverse reaction to fragrances (ie. they trigger a severe asthmatic attack or nausea).
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
250 participants (estimated)
Patient registry
No

Groups and cohorts

  • Subjective Cognitive Concerns (SCC)

    The composition of the proposed study population will reflect that of subjects recruited through the Longitudinal Cohort of the Massachusetts Alzheimer's Disease Research Center and that of patients treated by neurologists at the Memory and Movement Disorders Clinics at MGH as well as participants from the community.

    Device: AROMHA Brain Health Test

  • Mild Cognitive Impairment (MCI)

    The composition of the proposed study population will reflect that of subjects recruited through the Longitudinal Cohort of the Massachusetts Alzheimer's Disease Research Center and that of patients treated by neurologists at the Memory and Movement Disorders Clinics at MGH as well as participants from the community.

    Device: AROMHA Brain Health Test

  • Mild Behavioral Impairment [prominent apathy] (MBI)

    The composition of the proposed study population will reflect that of subjects recruited through the Longitudinal Cohort of the Massachusetts Alzheimer's Disease Research Center and that of patients treated by neurologists at the Memory and Movement Disorders Clinics at MGH as well as participants from the community.

    Device: AROMHA Brain Health Test

  • Age-matched Controls

    We will utilize community sampling to recruit 100 age-matched controls.

    Device: AROMHA Brain Health Test

Interventions

  • DeviceAROMHA Brain Health Test

    The AROMHA Brain Health Test is a self-administered, at-home smell test developed as a potential primary screen for identifying individuals at risk for developing Alzheimer's and as a means to follow disease progression in individuals without overt cognitive symptoms. The smell test device consists of five physical smell cards and a paired web-based app that directs participants on how to sample odors and asks them questions regarding what they have smelled. The 45-minute smell test battery includes measures of odor intensity, identification, memory, and discrimination.

06

What researchers measure

Primary outcomes

  1. AROMHA Brain Health Test

    The AROMHA Brain Health Test is a battery of 18 odors across 5 smell cards. The subject smells each odor label and is tested on odor intensity, identification, memory, and discrimination. An increased number of correct responses indicates a better sense of smell. We will evaluate MCI patients' performance against age-matched controls.

    Time frame: 1 hour

Secondary outcomes

  1. AROMHA Brain Health Test

    The AROMHA Brain Health Test is a battery of 18 odors across 5 smell cards. The subject smells each odor label and is tested on odor intensity, identification, memory, and discrimination. An increased number of correct responses indicates a better sense of smell. We will evaluate MBI patients' performance against age-matched controls.

    Time frame: 1 hour

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2023 (actual). Primary completion is estimated for Dec 2026, 43 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2023
First posted
May 31, 2023
StartActual
May 9, 2023
Primary completionEst.
Dec 30, 2026
CompletionEst.
Dec 31, 2027
Last update
Mar 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05881239
Responsible party
Mark W Albers (Frank Wilkens and Family Endowed Scholar/ Asst. Prof. Neurology, Massachusetts General Hospital) — Principal investigator
First posted
May 31, 2023
Start date
May 9, 2023
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Mar 6, 2026

Study contacts

Mark W Albers, MD PhD
Contact
albers.mark@mgh.harvard.edu
617-724-7401
Alefiya Albers, PhD
Contact
AALBERS@mgh.harvard.edu
Mark W Albers, MD PhD
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion